Psychedelics and Autism Therapy: A Review of Current Research and Future Directions.

Christopher S Gondi, Manu Gnanamony, Tarun P Gondi, Lilyt Nersesyan, Lusine Demirkhanyan

Abstract readReview

In one paragraph

Review in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher S GondiDepartments of Internal Medicine, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.ORCID 0000-0002-3036-9920

Manu GnanamonyDepartments of Pediatrics, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.ORCID 0000-0002-1893-6603

Tarun P GondiSchool of Communication and Media, University of Illinois Springfield, Springfield, IL 62703, USA.

Lilyt NersesyanDepartment of Clinical Psychology, College of Professional Psychology, The Chicago School, Chicago, IL 60654, USA.

Lusine DemirkhanyanDepartments of Internal Medicine, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.ORCID 0000-0002-3535-7996

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism Spectrum Disorder (ASD) is a lifelong condition marked by challenges in social communication and repetitive behaviors. Current treatments, primarily behavioral therapies, often fail to address the core symptoms. Recent research has explored the potential of psychedelics, such as LSD, psilocybin, and MDMA, as a new therapeutic approach. While these substances primarily modulate the serotonin 5-HT

Indexed as

Autism Spectrum Disorder (ASD)neuroplasticitypsychedelicsserotonin signalingtherapeutic potential

Identifiers

PMID42042077

DOI10.3390/cimb48040417

PMCPMC13115131

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.